Management of bleeding and invasive ...
Type de document :
Compte-rendu et recension critique d'ouvrage
DOI :
PMID :
Titre :
Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra (R)): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP)
Auteur(s) :
Susen, Sophie [Auteur]
Université de Lille
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U1011 [RNMCD]
Gruel, Yves [Auteur]
Godier, Anne [Auteur]
Innovations thérapeutiques en hémostase [IThEM - U1140]
Hôpital Européen Georges Pompidou [APHP] [HEGP]
Harroche, Annie [Auteur]
Hôpital Necker - Enfants Malades [AP-HP]
Chambost, Hervé [Auteur]
Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research [C2VN]
Service de pédiatrie, d'hématologie et d'oncologie [Hôpital de La Timone - APHM]
Lasne, Dominique [Auteur]
Hôpital Necker - Enfants Malades [AP-HP]
Rauch, Antoine [Auteur]
Université de Lille
Roullet, Stéphanie [Auteur]
Université de Bordeaux [UB]
Fontana, Pierre [Auteur]
Hôpitaux Universitaires de Genève [HUG]
Université de Genève = University of Geneva [UNIGE]
Goudemand, Jenny [Auteur]
Université de Lille
de Maistre, Emmanuel [Auteur]
Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand [CHU Dijon]
Chamouard, Valerie [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Wibaut, Bndicte [Auteur]
Université de Lille
Albaladejo, Pierre [Auteur]
Université Grenoble Alpes [2016-2019] [UGA [2016-2019]]
Negrier, Claude [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Université de Lille
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U1011 [RNMCD]
Gruel, Yves [Auteur]
Godier, Anne [Auteur]
Innovations thérapeutiques en hémostase [IThEM - U1140]
Hôpital Européen Georges Pompidou [APHP] [HEGP]
Harroche, Annie [Auteur]
Hôpital Necker - Enfants Malades [AP-HP]
Chambost, Hervé [Auteur]
Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research [C2VN]
Service de pédiatrie, d'hématologie et d'oncologie [Hôpital de La Timone - APHM]
Lasne, Dominique [Auteur]
Hôpital Necker - Enfants Malades [AP-HP]
Rauch, Antoine [Auteur]
Université de Lille
Roullet, Stéphanie [Auteur]
Université de Bordeaux [UB]
Fontana, Pierre [Auteur]
Hôpitaux Universitaires de Genève [HUG]
Université de Genève = University of Geneva [UNIGE]
Goudemand, Jenny [Auteur]
Université de Lille
de Maistre, Emmanuel [Auteur]
Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand [CHU Dijon]
Chamouard, Valerie [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Wibaut, Bndicte [Auteur]
Université de Lille
Albaladejo, Pierre [Auteur]
Université Grenoble Alpes [2016-2019] [UGA [2016-2019]]
Negrier, Claude [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Titre de la revue :
Haemophilia
Éditeur :
Wiley
Date de publication :
2019
ISSN :
1351-8216
Mot(s)-clé(s) en anglais :
bleeding
emergency
emicizumab
haemophilia
inhibitor
invasive procedures
proposals
emergency
emicizumab
haemophilia
inhibitor
invasive procedures
proposals
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Introduction Emicizumab (Hemlibra (R)) recently became available and requires an adaptation for managing bleeding, suspected bleeding and emergency or scheduled invasive procedures in haemophilia A patients with inhibitor. ...
Lire la suite >Introduction Emicizumab (Hemlibra (R)) recently became available and requires an adaptation for managing bleeding, suspected bleeding and emergency or scheduled invasive procedures in haemophilia A patients with inhibitor. This implicates a multidisciplinary approach and redaction of recommendations for care that must be regularly adapted to the available data. Aim The following text aims to provide a guide for the management of people with haemophilia A with inhibitor treated with emicizumab in case of bleeding or invasives procedures. Methods The French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia (CRH), in collaboration with the French Working Group on Perioperative Haemostasis (GIHP) have been working together to make proposals for the management of these situations. Results Haemostatic treatment and other medications should be given stepwise, according to the severity and location of the bleeding or the risk of bleeding of the procedure as well as the haemostatic response obtained at each step in order to ensure an optimal benefit/risk ratio. Conclusion The lack of data means that it is only possible to issue proposals rather than recommendations.Lire moins >
Lire la suite >Introduction Emicizumab (Hemlibra (R)) recently became available and requires an adaptation for managing bleeding, suspected bleeding and emergency or scheduled invasive procedures in haemophilia A patients with inhibitor. This implicates a multidisciplinary approach and redaction of recommendations for care that must be regularly adapted to the available data. Aim The following text aims to provide a guide for the management of people with haemophilia A with inhibitor treated with emicizumab in case of bleeding or invasives procedures. Methods The French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia (CRH), in collaboration with the French Working Group on Perioperative Haemostasis (GIHP) have been working together to make proposals for the management of these situations. Results Haemostatic treatment and other medications should be given stepwise, according to the severity and location of the bleeding or the risk of bleeding of the procedure as well as the haemostatic response obtained at each step in order to ensure an optimal benefit/risk ratio. Conclusion The lack of data means that it is only possible to issue proposals rather than recommendations.Lire moins >
Langue :
Anglais
Vulgarisation :
Non
Source :